464 related articles for article (PubMed ID: 26044126)
41. All-trans-retinoic acid improves cholestasis in α-naphthylisothiocyanate-treated rats and Mdr2-/- mice.
Cai SY; Mennone A; Soroka CJ; Boyer JL
J Pharmacol Exp Ther; 2014 Apr; 349(1):94-8. PubMed ID: 24492652
[TBL] [Abstract][Full Text] [Related]
42. Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in taurolithocholic acid-induced cholestasis in rat liver.
Denk GU; Maitz S; Wimmer R; Rust C; Invernizzi P; Ferdinandusse S; Kulik W; Fuchsbichler A; Fickert P; Trauner M; Hofmann AF; Beuers U
Hepatology; 2010 Nov; 52(5):1758-68. PubMed ID: 21038414
[TBL] [Abstract][Full Text] [Related]
43. Metformin slows liver cyst formation and fibrosis in experimental model of polycystic liver disease.
Sato Y; Qiu J; Hirose T; Miura T; Sato Y; Kohzuki M; Ito O
Am J Physiol Gastrointest Liver Physiol; 2021 Apr; 320(4):G464-G473. PubMed ID: 33439105
[TBL] [Abstract][Full Text] [Related]
44. Liver protective effect of ursodeoxycholic acid includes regulation of ADAM17 activity.
Buryova H; Chalupsky K; Zbodakova O; Kanchev I; Jirouskova M; Gregor M; Sedlacek R
BMC Gastroenterol; 2013 Oct; 13():155. PubMed ID: 24172289
[TBL] [Abstract][Full Text] [Related]
45. Ursodeoxycholic acid choleresis: relationship to biliary HCO-3 and effects of Na+-H+ exchange inhibitors.
Renner EL; Lake JR; Cragoe EJ; Van Dyke RW; Scharschmidt BF
Am J Physiol; 1988 Feb; 254(2 Pt 1):G232-41. PubMed ID: 2831731
[TBL] [Abstract][Full Text] [Related]
46. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles.
Fickert P; Zollner G; Fuchsbichler A; Stumptner C; Weiglein AH; Lammert F; Marschall HU; Tsybrovskyy O; Zatloukal K; Denk H; Trauner M
Gastroenterology; 2002 Oct; 123(4):1238-51. PubMed ID: 12360485
[TBL] [Abstract][Full Text] [Related]
47. The pck rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease.
Lager DJ; Qian Q; Bengal RJ; Ishibashi M; Torres VE
Kidney Int; 2001 Jan; 59(1):126-36. PubMed ID: 11135065
[TBL] [Abstract][Full Text] [Related]
48. Abnormal expression of MUC1 apomucin and mature MUC1 mucin in biliary epithelial cells in various cystic liver diseases.
Sasaki M; Nakanuma Y
Hepatology; 1996 Sep; 24(3):539-43. PubMed ID: 8781320
[TBL] [Abstract][Full Text] [Related]
49. Omega-3 Polyunsaturated Fatty Acid: A Pharmaco-Nutraceutical Approach to Improve the Responsiveness to Ursodeoxycholic Acid.
Thérien A; Cieślak A; Verreault M; Perreault M; Trottier J; Gobeil S; Vohl MC; Barbier O
Nutrients; 2021 Jul; 13(8):. PubMed ID: 34444777
[TBL] [Abstract][Full Text] [Related]
50. Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver.
Fickert P; Zollner G; Fuchsbichler A; Stumptner C; Pojer C; Zenz R; Lammert F; Stieger B; Meier PJ; Zatloukal K; Denk H; Trauner M
Gastroenterology; 2001 Jul; 121(1):170-83. PubMed ID: 11438506
[TBL] [Abstract][Full Text] [Related]
51. Effect of oral ursodeoxycholic acid on bile acids tolerance tests in healthy dogs.
Abraham LA; Charles JA; Holloway SA
Aust Vet J; 2004 Mar; 82(3):157-60. PubMed ID: 15088982
[TBL] [Abstract][Full Text] [Related]
52. Effects of ursodeoxycholic acid on synthesis of cholesterol and bile acids in healthy subjects.
Sauter GH; Thiessen K; Parhofer KG; Jüngst C; Fischer S; Jüngst D
Digestion; 2004; 70(2):79-83. PubMed ID: 15375335
[TBL] [Abstract][Full Text] [Related]
53. TGR5 in the Cholangiociliopathies.
Masyuk TV; Masyuk AI; LaRusso NF
Dig Dis; 2015; 33(3):420-5. PubMed ID: 26045278
[TBL] [Abstract][Full Text] [Related]
54. Long-Term Ursodeoxycholic Acid Therapy Does Not Alter Lithocholic Acid Levels in Patients with Cystic Fibrosis with Associated Liver Disease.
Colombo C; Crosignani A; Alicandro G; Zhang W; Biffi A; Motta V; Corti F; Setchell KDR
J Pediatr; 2016 Oct; 177():59-65.e1. PubMed ID: 27297203
[TBL] [Abstract][Full Text] [Related]
55. Regulation of rat organic anion transporters in bile salt-induced cholestatic hepatitis: effect of ursodeoxycholate.
Rost D; Herrmann T; Sauer P; Schmidts HL; Stieger B; Meier PJ; Stremmel W; Stiehl A
Hepatology; 2003 Jul; 38(1):187-95. PubMed ID: 12830001
[TBL] [Abstract][Full Text] [Related]
56. Ursodeoxycholate further increases bile-duct cell proliferative response induced by partial bile-duct ligation in rats.
Barone M; Maiorano E; Ladisa R; Pece A; Berloco P; Strazzabosco M; Caruso ML; Valentini AM; Ierardi E; Di Leo A; Francavilla A
Virchows Arch; 2004 Jun; 444(6):554-60. PubMed ID: 15071740
[TBL] [Abstract][Full Text] [Related]
57. 3alpha-6alpha-Dihydroxy-7alpha-fluoro-5beta-cholanoate (UPF-680), physicochemical and physiological properties of a new fluorinated bile acid that prevents 17alpha-ethynyl-estradiol-induced cholestasis in rats.
Clerici C; Castellani D; Asciutti S; Pellicciari R; Setchell KD; O'Connell NC; Sadeghpour B; Camaioni E; Fiorucci S; Renga B; Nardi E; Sabatino G; Clementi M; Giuliano V; Baldoni M; Orlandi S; Mazzocchi A; Morelli A; Morelli O
Toxicol Appl Pharmacol; 2006 Jul; 214(2):199-208. PubMed ID: 16487557
[TBL] [Abstract][Full Text] [Related]
58. Bile Acids as Signaling Molecules: Role of Ursodeoxycholic Acid in Cholestatic Liver Disease.
Cifuentes-Silva E; Cabello-Verrugio C
Curr Protein Pept Sci; 2024; 25(3):206-214. PubMed ID: 37594109
[TBL] [Abstract][Full Text] [Related]
59. Ursodeoxycholic acid treatment of vanishing bile duct syndromes.
Pusl T; Beuers U
World J Gastroenterol; 2006 Jun; 12(22):3487-95. PubMed ID: 16773706
[TBL] [Abstract][Full Text] [Related]
60. Stimulation of ATP secretion in the liver by therapeutic bile acids.
Nathanson MH; Burgstahler AD; Masyuk A; Larusso NF
Biochem J; 2001 Aug; 358(Pt 1):1-5. PubMed ID: 11485545
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
